Clinical Trial: Evaluation of Gallium-68 DOTA-TOC Imaging of Somatostatin Receptor Positive Malignancies
Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional
Official Title: Evaluation of Gallium-68 DOTA-TOC Imaging of Somatostatin Receptor Positive Malignancies
Brief Summary: The primary objective of this study is to determine if Gallium-68 labeled DOTA-TOC will result in the delineation of more lesions in patients with somatostatin receptor positive malignancies than with conventional imaging.
Detailed Summary:
Sponsor: University of California, San Francisco
Current Primary Outcome: Number of lesions visualized [ Time Frame: 24 hours from injection of DOTA-TOC ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: University of California, San Francisco
Dates:
Date Received: June 25, 2014
Date Started: June 2014
Date Completion:
Last Updated: May 11, 2016
Last Verified: May 2016